Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles M Alexander

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
The American Journal of Managed Care|October 25, 2002
Growth in use of lipid-lowering therapies: are we targeting the right patients?Robert W Dubois, Charles M Alexander, Sally Wade, et al.
Diabetes Care|March 29, 2003
Trends in lipid management among patients with coronary artery disease: has diabetes received the attention it deserves?Mark W Massing, Kathleen A Foley, Carla A Sueta, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 15, 2015
A survey of patient preferences for oral antihyperglycemic therapy in patients with type 2 diabetes mellitusA Brett Hauber, Kaan Tunceli, Jui-Chen Yang, et al.
The American Journal of Cardiology|March 23, 2005
Estimating cholesterol treatment rates among individuals with multiple risk factors and without coronary heart diseaseSoma S Nag, Thomas A Pearson, Larry Ma, et al.
Diabetes Care|November 25, 2004
End-stage renal disease-associated managed care costs among patients with and without diabetesAmie T Joyce, John M Iacoviello, Soma Nag, et al.
Pharmacoeconomics|June 10, 2006
The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathyGeorge W Carides, Shahnaz Shahinfar, Erik J Dasbach, et al.
Preventing Chronic Disease|June 21, 2005
Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settingsPatrick J O'Connor, Richard J Gray, Michael V Maciosek, et al.
The American Journal of Managed Care|November 20, 2002
Do disease management programs for patients with coronary heart disease make a difference? Experiences of nine practicesMary N Walsh, Ross J Simpson, George J Wan, et al.
Diabetes Care|March 1, 2003
Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluationWilliam H Herman, Shahnaz Shahinfar, George W Carides, et al.
Patient Preference and Adherence|October 3, 2013
Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetesA Brett Hauber, Steven Han, Jui-Chen Yang, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
The American Journal of Managed Care|October 25, 2002
Growth in use of lipid-lowering therapies: are we targeting the right patients?Robert W Dubois, Charles M Alexander, Sally Wade, et al.
Diabetes Care|March 29, 2003
Trends in lipid management among patients with coronary artery disease: has diabetes received the attention it deserves?Mark W Massing, Kathleen A Foley, Carla A Sueta, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 15, 2015
A survey of patient preferences for oral antihyperglycemic therapy in patients with type 2 diabetes mellitusA Brett Hauber, Kaan Tunceli, Jui-Chen Yang, et al.
The American Journal of Cardiology|March 23, 2005
Estimating cholesterol treatment rates among individuals with multiple risk factors and without coronary heart diseaseSoma S Nag, Thomas A Pearson, Larry Ma, et al.
Diabetes Care|November 25, 2004
End-stage renal disease-associated managed care costs among patients with and without diabetesAmie T Joyce, John M Iacoviello, Soma Nag, et al.
Pharmacoeconomics|June 10, 2006
The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathyGeorge W Carides, Shahnaz Shahinfar, Erik J Dasbach, et al.
Preventing Chronic Disease|June 21, 2005
Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settingsPatrick J O'Connor, Richard J Gray, Michael V Maciosek, et al.
The American Journal of Managed Care|November 20, 2002
Do disease management programs for patients with coronary heart disease make a difference? Experiences of nine practicesMary N Walsh, Ross J Simpson, George J Wan, et al.
Diabetes Care|March 1, 2003
Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluationWilliam H Herman, Shahnaz Shahinfar, George W Carides, et al.
Patient Preference and Adherence|October 3, 2013
Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetesA Brett Hauber, Steven Han, Jui-Chen Yang, et al.
Pageof 5